Core Viewpoint - The company, Giant Bio (02367.HK), has received a medical device registration certificate from the National Medical Products Administration of China for its recombinant type I α1 collagen and sodium hyaluronate composite solution, marking a significant advancement in its product offerings [1] Group 1: Product Approval - The product is the world's first recombinant collagen and sodium hyaluronate composite solution approved for improving cheek smoothness, indicating a pioneering position in the market [1] - The approval was achieved through a joint review of device and drug assessments, showcasing the company's robust regulatory compliance [1] Group 2: Market Expansion - The successful approval of this product expands the company's product matrix and highlights its ongoing technological research and industrialization capabilities [1] - The company aims to promote the product's market launch and distribution, leveraging a diverse product portfolio, comprehensive channel network, and refined brand management to meet consumer demands in various scenarios [1] - This development is expected to inject new growth momentum into the company's business in the skin rejuvenation sector, reinforcing its leading market position in health and beauty [1]

Core Viewpoint - The company has received a medical device registration certificate from the National Medical Products Administration of China for its recombinant type I α1 collagen and sodium hyaluronate composite solution, marking a significant milestone in its product development and market expansion [1] Product Development - The product is the world's first recombinant collagen and sodium hyaluronate composite solution approved for improving cheek smoothness, showcasing the company's innovative capabilities [1] - This approval follows the successful registration of the recombinant type I α1 collagen freeze-dried fiber, further expanding the company's product matrix [1] Market Strategy - The company aims to steadily promote the product's market launch and distribution, leveraging a diverse product portfolio, comprehensive channel network, and refined brand management [1] - The introduction of this product is expected to inject new growth momentum into the company's business development in the skin rejuvenation sector [1]

继重组I型α1亚型胶原蛋白冻干纤维之后，本产品的成功获批进一步拓展了本公司的产品矩阵，体现了 集团持续领先的技术研发和产业化实力，同时打开了更广阔的市场空间，为本公司在肌肤焕活领域的业 务发展注入新的增长动力。未来，本公司将稳步推进上述产品的上市推广与市场投放工作，通过多元的 产品组合、全面的渠道网络、精细的品牌运营，为更多场景下的消费者需求提供差异化的解决方案，不 断强化本公司在健康与美丽领域的领先市场地位。 本产品是全球首个用于改善面颊部平滑度的重组胶原蛋白和透明质酸钠复合溶液植入剂产品，通过器审 与药审联合审评正式获批。 智通财经APP讯，巨子生物(02367)发布公告，本公司全资子公司陕西巨子生物技术有限公司于今日收到 中国国家药品监督管理局颁发的关于重组I型α1亚型胶原蛋白及透明质酸钠复合溶液产品(本产品)的 《中华人民共和国医疗器械注册证》(注册证编号：国械注准20263130044)。本产品以重组胶原蛋白及 透明质酸钠为主要成分，用于真皮层的注射，以改善面颊部平滑度。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 GIANT BIOGENE HOLDING CO., LTD 巨子生物控股有限公司 （於 開 曼 群 島 註 冊 成 立 的 獲 豁 免 有 限 公 司） （股 份 代 號：2367） 本 公 司 欣 然 宣 布，本 公 司 全 資 子 公 司 陝 西 巨 子 生 物 技 術 有 限 公 司 於 今 日 收 到 中國國家藥品監督管理局頒發的關於重組I型α1亞型膠原蛋白及透明質酸鈉 複合溶液產品（「本產品」）的《中 華 人 民 共 和 國 醫 療 器 械 註 冊 證》（註 冊 證 編 號：國 械註准20263130044）。本 產 品 以 重 組 膠 原 蛋 白 及 透 明 質 酸 鈉 為 主 要 成 分，用 於 真 皮 層 的 注 射，以 改 善 面 頰 部 平 滑 度。 本產品是全球首個用於改善面頰部平滑度的重組膠原蛋白和透明質酸鈉複合 溶 液 ...

Core Viewpoint - The company is optimistic about the recombinant collagen market, highlighting its advantages in safety, efficacy, and sustainability, which are seen as fundamental drivers for industry development [1] Group 1: Industry Insights - Recombinant collagen production occurs in controlled fermentation environments, mitigating risks associated with animal-derived collagen, such as viral transmission and allergic reactions [1] - The technology allows for precise production of recombinant collagen with specific amino acid sequences, enhancing targeted efficacy for various applications, including anti-wrinkle and tissue regeneration [1] - The fermentation process offers scalability and consistency, enabling low-cost, high-quality production, thus overcoming limitations faced by animal-derived collagen [1] Group 2: Company Performance - The company operates six brands centered around recombinant collagen, with key brands contributing over 95% of revenue; projected revenues for 2024 are 4.54 billion and 840 million for the two main brands, with compound annual growth rates of 73.4% and 11.8% respectively from 2021 to 2024 [2] - The company is facing short-term operational pressures due to market discussions surrounding the content and testing methods of recombinant collagen, impacting brand performance, particularly for its flagship product [2] - The company is shifting from reliance on a single product to a strategy of "multiple brands, multiple categories, and multiple channels" to address challenges [2] Group 3: Product Development and Market Strategy - Plans for 2026 include launching a medical device and five skincare lines, with marketing efforts focused on core products [3] - The company aims to enhance its brand presence through collaborations and expanding its retail footprint, including increasing coverage in approximately 150,000 pharmacies nationwide [3] - The medical aesthetics sector is identified as a strategic growth area, with plans to establish a dedicated division and expand into around 2,000 medical aesthetic institutions by 2026 [3] Group 4: Financial Projections - The company is rated "outperform" with a target price of 43.6 HKD, indicating a potential upside of 22.0%; revenue projections for 2025-2027 are 5.49 billion, 5.99 billion, and 6.69 billion respectively, with expected growth rates of -0.9%, 9.1%, and 11.8% [4] - Gross margins are projected to remain stable at around 80.5% to 79.2% from 2025 to 2027, while net profit margins are expected to decline slightly [4]

Summary of Key Points Core Viewpoint - On January 14, 39 Hong Kong-listed companies conducted share buybacks, totaling 20.28 million shares and an aggregate amount of HKD 919 million [1]. Group 1: Buyback Details - Tencent Holdings repurchased 1.006 million shares for HKD 636 million, with a highest price of HKD 638.00 and a lowest price of HKD 626.00, bringing its year-to-date buyback total to HKD 57.22 billion [1]. - Xiaomi Group-W repurchased 4 million shares for HKD 151 million, with a highest price of HKD 37.80 and a lowest price of HKD 37.72, accumulating HKD 10.93 billion in buybacks year-to-date [1]. - Sunny Optical Technology repurchased 1.14 million shares for HKD 74.41 million, with a highest price of HKD 66.15 and a lowest price of HKD 64.05, totaling HKD 3.03 billion in buybacks year-to-date [1]. Group 2: Buyback Rankings - The highest buyback amount on January 14 was from Tencent Holdings at HKD 636 million, followed by Xiaomi Group-W at HKD 151 million [1]. - In terms of buyback volume, Xiaomi Group-W led with 4 million shares, followed by First Capital Holdings and Jieli Trading at 2.7 million and 2 million shares, respectively [1]. Group 3: Additional Buyback Activities - Other notable companies involved in buybacks include: - Giant Bio at 400,000 shares for HKD 1.415 million [1]. - Country Garden Services at 1 million shares for HKD 624,260 [1]. - First Capital Holdings at 2.7 million shares for HKD 561,130 [1].

| 手回集团(02621) | 1.44 万 | 5.13 万 | 42.96 万 | | | --- | --- | --- | --- | --- | | 华检医疗(01931) | 2.00 万 | 5.06 万 | 1653.40 万 | 1.020% | | 美亨实业(01897) | 10.00 万 | 4.80 万 | 162.80 万 | 0.400% | | 天福(06868) | 1.70 万 | 4.40 万 | 69.00 万 | 0.064% | | 九源基因(02566) | 3000.00 | 2.47 万 | 3.30 万 | 0.030% | | 滨海投资(02886) | 1.80 万 | 2.07 万 | 229.80 万 | 0.167% | | 同方友友(01868) | 4.60 万 | 1.83 万 | 168.40 万 | 0.080% | | 天润云(02167) | 4000.00 | 1.83 万 | 10.72 万 | 0.062% | | 乐声电子(00213) | 3.00 万 | 1.06 万 | 81.60 万 | 0.089% | | 摩比发展 ...

（原标题：巨子生物(02367.HK)连续8日回购，累计回购320.00万股） 证券时报•数据宝统计，巨子生物在港交所公告显示，1月14日以每股35.100港元至35.800港元的价格回购40.00万股，回购金额达1415.00万港元。 该股当日收盘价35.220港元，下跌1.45%，全天成交额2.70亿港元。 自1月5日以来公司已连续8日进行回购，合计回购320.00万股，累计回购金额1.11亿港元。 其间该股累计上涨2.92%。（数据宝） 巨子生物回购明细 | 日期 | 回购股数 （万股） | 回购最高价 （港元） | 回购最低价 （港元） | 回购金额 （万港元） | | --- | --- | --- | --- | --- | | 2026.01.14 | 40.00 | 35.800 | 35.100 | 1415.00 | | 2026.01.13 | 40.00 | 36.200 | 35.640 | 1433.78 | | 2026.01.12 | 40.00 | 35.500 | 34.500 | 1400.29 | | 2026.01.09 | 40.00 | 34.580 | 34.2 ...

巨子生物(02367)发布公告，于2026年1月14日，该公司斥资1415万港元回购40万股股份，每股回购价格 为35.1-35.8港元。 ...

格隆汇1月14日丨巨子生物(02367.HK)公告，1月14日耗资1415万港元回购40万股，每股回购价35.1-35.8 港元。 ...